Results 1 to 10 of about 2,342,069 (298)

Glutathione S‐transferase omega class 1 (GSTO1)‐associated large extracellular vesicles are involved in tumor‐associated macrophage‐mediated cisplatin resistance in bladder cancer

Molecular Oncology
Bladder cancer poses a significant challenge to chemotherapy due to its resistance to cisplatin, especially at advanced stages. Understanding the mechanisms behind cisplatin resistance is crucial for improving cancer therapy.
Yi‐Cheng Pan, Pei‐Yi Chu, Ching‐Chan Lin, Ching‐Yun Hsieh, Wei‐Yu Hsu, Lie‐Fen Shyur, Juan‐Cheng Yang, Wei‐Chao Chang, Yang‐Chang Wu   +8 more
doaj   +1 more source

SERBP1 is required for efficient HR repair and cisplatin chemoresistance in lung adenocarcinoma

Cell Death Discovery
Resistance to cisplatin limits its clinical efficacy in LUAD patients and leads to poor prognosis. SERPINE1 mRNA binding protein 1 (SERBP1), an RNA-binding protein, is associated with tumorigenesis and progression. However, its specific role in cisplatin
Yifei Xie, Qiongju Chen, Nana Tang, Yuanyuan Zeng, Jian Zhao, Yang Yang, Chang Li, Jianjun Li, Jianjie Zhu, Jian-an Huang, Zeyi Liu   +10 more
doaj   +1 more source

Long non-coding RNAs MACC1-AS1 and FOXD2-AS1 mediate NSD2-induced cisplatin resistance in esophageal squamous cell carcinoma

Molecular Therapy: Nucleic Acids, 2021
The nuclear receptor-binding SET domain (NSD) protein family encoding histone lysine methyltransferases is involved in cancer progression. However, the role of NSDs in esophageal squamous cell carcinoma (ESCC) remains unclear.
Wenhua Xue, Zhibo Shen, Lifeng Li, Yuanyuan Zheng, Dan Yan, Quancheng Kan, Jie Zhao   +6 more
doaj   +1 more source

VANGL2 downregulates HINT1 to inhibit the ATM-p53 pathway and promote cisplatin resistance in small cell lung cancer

Cell Death Discovery
Cisplatin is a first-line drug for the treatment of small cell lung cancer (SCLC). Although the majority of patients with SCLC initially respond to cisplatin therapy, cisplatin resistance readily develops, leading to tumor progression.
Jiayi Xie, Huiying Liu, Chunqian Yang, Weitao Shen, Jian Zhang   +4 more
doaj   +1 more source

Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer

Chinese Journal of Lung Cancer, 2023
As one of the most common malignant tumors, lung cancer poses a serious threat to human life and health. The platinum-based drug cisplatin (DDP) is used as the first-line treatment for lung cancer.
Jinzhe SUN, Jun CHEN
doaj   +1 more source

The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.

PLoS ONE, 2013
Resistance to cisplatin-based therapy is a major cause of treatment failure in human ovarian cancer. A better understanding of the mechanisms of cisplatin resistance will offer new insights for novel therapeutic strategies for this deadly disease.
Akechai Im-aram, Lee Farrand, Seung-Min Bae, Gwonhwa Song, Yong Sang Song, Jae Yong Han, Benjamin K Tsang   +6 more
doaj   +1 more source

ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway

Journal of Experimental & Clinical Cancer Research, 2018
Background ER-α36, a novel ER-α66 variant, has been demonstrated to promote tamoxifen resistance in breast cancer cells. However, the role and mechanisms of ER-α36 in cisplatin resistance of breast cancer cells remain unclear. This study investigates the
Linlin Zhu, Jiao Zou, Yuanyin Zhao, Xiaomei Jiang, Yang Wang, Xiangwei Wang, Bin Chen   +6 more
doaj   +1 more source

Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. [PDF]

PLoS ONE, 2014
Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance.
Chi T Viet, Dongmin Dang, Stacy Achdjian, Yi Ye, Samuel G Katz, Brian L Schmidt   +5 more
doaj   +1 more source

p32/OPA1 axis-mediated mitochondrial dynamics contributes to cisplatin resistance in non-small cell lung cancer

Acta Biochimica et Biophysica Sinica, 2023
Cisplatin resistance is a major obstacle in the treatment of non-small cell lung cancer (NSCLC). p32 and OPA1 are the key regulators of mitochondrial morphology and function. This study aims to investigate the role
Yu Chun-Xia, Peng Zhe-Qing, Wang Tao, Qu Xin-Hui, Yang Ping, Huang Shao-Rong, Jiang Li-Ping, Tou Fang-Fang, Han Xiao-Jian   +8 more
doaj   +1 more source

MTMR6 downregulation contributes to cisplatin resistance in oral squamous cell carcinoma

Cancer Cell International
Background The therapeutic effectiveness of cisplatin, a widely used chemotherapy drug for oral squamous cell carcinoma (OSCC), is often compromised by resistance, making it difficult to predict treatment outcomes.
Kah Young Lee, Su Young Oh, Heon-Jin Lee, Tae-Geon Kwon, Jin-Wook Kim, Chang-Geol Shin, Su-Hyung Hong, So-Young Choi   +7 more
doaj   +1 more source